Cell signalling
Which STAT partners dominate cancer signaling networks?
Open access · cc by · source: Europe PMC
An IID-based interactome shows STAT3 as the busiest hub, STAT1 as a frequent antagonist, and points to cytoplasmic nodes for JAK/STAT-targeted therapy ideas.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Study at a glance
- Design
- Computational / modelling — IID 2018 literature-curated STAT PPI interactomes filtered by disease/tissue expression context and visualized with NAViGaTOR
- N
- Network counts of STAT partners (e.g., STAT3 n=166 proteins) rather than a patient cohort N
- Population
- Curated human STAT protein–protein interactions across major cancer contexts
- Outcome
- Member-specific STAT interactomes and proposed targeting points in oncogenic JAK/STAT signaling
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Which STAT partners dominate cancer signaling networks?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
What kind of analysis did the authors perform on STAT-linked disease data?
Through a comprehensive review and in silico analysis of reported data on STAT‐linked diseases
Which database supplied curated PPIs?
These data were collected using the integrated interactions database (IID) 2018 version
Key findings
STAT3 had the largest diversity (166 partners) vs STAT1 (81); STAT3/5 emerge as pleiotropic oncogenes while STAT1 often counters STAT3; EGFR/ESR1 interplay and cytoplasmic hubs inform targeting hypotheses.
Methodology
Using IID 2018 PPIs (stringent multi-evidence + expression context), the authors built global and cancer-specific STAT interactomes and mapped them with NAViGaTOR, integrating literature on STAT-linked diseases.
Limitations
Not a clinical drug trial; missing edges may reflect study bias, and network centrality ≠ proven drug efficacy.
Related papers in this topic
Same topic cluster — not a recommendation engine.